Building on our early findings up to 8 weeks, this update covers progress through week 12, highlighting how our specialized creep and nursery feeds, enhanced with additives for mucosal immunity and protein synthesis, are making a tangible difference.
Trial Overview
Two groups of nursery piglets were compared:
Both groups were exposed to PRRS infection during the period—creating a real-world, high-stress testing scenario.
Growth Performance Highlights
Despite both groups being affected by PRRS, the BiomiXin-fed B2 group consistently outperformed the control group across multiple key indicators:
The B2 Trial Group demonstrated outstanding performance across all key indicators, achieving a 24.3% higher survival rate. Despite using less feed, B2 still delivered better growth outcomes, including higher transfer weights at week 12. More importantly, it showed a significant reduction in disease-related mortality, with the PRRS Mortality Share dropping by 75.1% and the Emaciation Mortality Share reduced by 63.6%, indicating healthier pigs and fewer losses among those that did not survive.
These results highlight the strong synergy between feed efficiency, animal health, and economic benefit under the B2 feeding strategy.
Additionally, since BiomiXin’s creep and nursery feeds were formulated at the same cost level as the farm’s original feeds, any reduction in feed consumption translates directly into cost savings—making the performance gains not only biological, but financially meaningful as well.
B1: Control Group (Left)
Piglets appear lethargic and huddled closely together, a sign they may be experiencing cold stress or reduced energy levels. Several individuals show rougher coat texture and signs of uneven development.
B2: Trial Group (Right)
Piglets display more upright posture and are actively exploring or feeding—suggesting better energy levels, comfort, and overall well-being. Their body condition appears fuller and more uniform, with smoother coat texture. The brighter behavior and robust appearance reflect stronger immune status and better nutrient utilization—hallmarks of a well-performing nursery feed program.
Looking Ahead: Growing Together, One Step at a Time
This first phase is just the beginning. The success of the B2 trial—marked by lower mortality, improved growth, and meaningful cost savings—has given us more than promising data.
We will continue expanding the trial across more pens and timeframes, monitoring not only performance metrics like weight and feed efficiency, but also deeper indicators such as viral load, antibody responses, and real-time barn feedback. These insights will guide us in refining our feed protocols to meet real-world challenges—together.
By sharing transparent updates and listening to farmers, we aim to refine solutions that deliver lasting value. At BiomiXin, trust is earned through results. Stay tuned as we continue this journey together. 💪💪💪